TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03990896: Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Sponsor: Massachusetts General Hospital · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,524,600

Rescue Site Savings

+$1,016,400

Unlock Full NCT03990896 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03990896 Rescue Dossier →